1
Development of Hereditary Cancer Prevention Measures in Pskov Region
Asoc. Prof. Edvīns Miklaševičs, Riga Stradins University
16 November 2011, St.Petersburg, Russia
2
Cancer is the second leading cause of death in Latvia and Russia
Hereditary cancer (HC) accounts for 5-20% of all cancers
The lifetime risk of developing cancer disease for carriers of cancer predisposing mutations is up to 80%, or 10-20 times higher than for the rest of the population
Unlike other forms of cancer, HC is the type of cancer that can and should be prevented
Background on hereditary cancer
3
Family A075
III:142
BRCA1(+)
III:2
IV:1 IV:223
BRCA1(+)
II:1 II:2Ov 50d 52
III:3
I:1 I:2
II:3 II:4Ut 52
II:5Br 54 Ov 54,5
d 55
II:6II:7
III:4Ov 46
III:5
IV:3 IV:4
4
BRCA1 and BRCA2
Mutations in the BRCA1 and BRCA2 genes predispose carriers to cancer at specific sites (breast, ovary)
Mutations are dominant, inheritance of one mutated allele is sufficient for cancer predisposition
Approx. 70 to 80 per cent of women carrying mutant alleles develop cancer
5
4154delAGronwald et al., 2005
5382insC
4153delAGayther et al., 1997
300T>G
5382insC
4153delAGórsky et al., 2000
5382insC
4153delATikhomirova et al., 2005
Gardovskis et al., 2005
300T>G
5382insC
4153delA
Oszurek et al., 2001
9
Why to detect mutation?Prophylactic measures
»regular medical check-ups
»no oral contraception
»breast feeding
»family planning and prophylactic bilateral salpingophorectomy
Strategy of operation and post-op therapy
»extent of operation
»effectivness of pharmaceuticals
Removing of family curse
10
Clinical case, BRCA1 c.5266dupC
Patient V., 28 years old
Breast cancer pT1N0M0 in 2008
»Mastectomy (right) in 2008
»Cis-platin and doxorubicin
Risk reducing surgery (left) with reconstruction in 2009/2010
11
Clinical case, BRCA1 c.4034delA
Patient S., 42 years old in 2003
Risk reducing adnexectomy in 2003
No oncological disease (2011)
12
Two partners – Riga Stradins University (RSU) and Pskov Oncological Dispensary (POD)
Transfer of knowledge and expertise in hereditary cancer treatment
Project duration – 24 months
Project budget – 297,176 EUR
Project in brief
13
The overall objective - to improve life quality in project area by developing effective population based hereditary cancer screening and management system model and combating hereditary cancer
Specific objectives:
» to ensure information and experience exchange about HC, its preventative measures and management;
» to raise awareness on HC as manageable and curable disease;
» to identify high HC risk individuals through HC screening pilot project
» to develop HC prevention and management base in Pskov.
Project objectives
14
The HC cases remain high not because of lack of scientific knowledge, but rather limited knowledge and experience exchange within the greater community of cancer specialists
Recently new and alternative methods for HC management have been introduced and are efficiently used in Latvia
The project aims at transferring the best practice from Latvian HC specialists to colleauges in Pskov
Situation in hereditary cancer treatment
15
Work package 1 deals with project management and financial management
Work package 2 will include publicity and visibility actions:
» Opening and closing conferences in Pskov
» Website development in Pskov
» Information updates on partner websites
» 2,000 doctor brochures and 20,000 patient brochures published and distributed in Pskov region
Work package 1 and Work package 2
16
2 experience exchange visits of Russian specialists in Riga, at the Hereditary Cancer Institute of RSU (5 participants)
2 joint seminars together with Latvian partners in Riga (around 15-20 participants)
Methodology for HC treatment in Pskov region developed
Work package 3 - transfer of knowledge on HC management
17
Establishment of the HC treatment centre in Pskov:
» Clinical part for providing consultations, preventive measures and treatment
» Molecular laboratory for carrying out diagnostic tests (procurement of necessary equipment)
» Tailor-made training programme for head of POD molecular laboratory in Riga, at the Hereditary Cancer Institute
After the project end the HC centre in Pskov will be open to the HC patients and analyses will be made and consultations provided on a regular basis
Work package 3 - development of HC centre in Pskov
18
The pilot project will include hospital screenings and registry screenings of patients in POD
1000 breast and ovarian cancer patients will be given family cancer history survey and taken blood sample
The DNA isolations for HC patients and their relatives from the acquired blood samples and BRCA1 founder mutation investigations will be carried out on 500 samples in LV and RU, thus ensuring that results of the test can be compared
For the 10 individuals with the highest risk full sequencing of the BRCA1/2 and MLH1, MSH2, MSH6 genes will be carried out
Work package 4 - Pilot project for the hereditary cancer screening and management
19
HC data base will be established, where during the project all the data from the pilot project will be assembled
A program which can calculate person’s HC risk based on family cancer history surveys and DNA data will be established and made compatible with the existing POD oncology disease patient data base
The system will provide dynamic, medical observation not only for patients with oncology illnesses, but also persons of the risk group
Work package 4 - Pilot project for the hereditary cancer screening and management
20
The methodology for carrying out consultations of HC patients will be developed and Latvian experts will visit Pskov to assist Russian colleagues carrying out consultations
The joint consultations will provide Russian specialists with knowledge on how to carry out consultations independently after the project end
Experience from the pilot project will allow to carry out population screening of Pskov region with the aim to discover HC cases and offer treatment possibilities to HC patients and HC high-risk individuals
Work package 4 - Pilot project for the hereditary cancer screening and management